Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Cancer02:18

Cancer

51.3K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
51.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

791
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
791
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.3K
Cancer Vaccines01:30

Cancer Vaccines

592
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
592
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lysosome self-sorting nanodegraders for hepatic clearance of pathogenic serum mediators.

Nature nanotechnology·2026
Same author

Burst-Mode Near-Infrared Chemiluminescent Probes for In Vivo Imaging.

Journal of the American Chemical Society·2026
Same author

Urinary fluorogenic reporters for noninvasive detection and staging of kidney fibrosis.

Science translational medicine·2026
Same author

Molecular rotor-based probes for protein monitoring in biomedical research.

Nature reviews. Chemistry·2026
Same author

Bioorthogonal Fluorogenic Reporters for Noninvasive Imaging and Urinalysis of Immunotherapeutic Response in Renal Cell Carcinoma.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Serum-Inert Tandem-Locked Fluorescent Probe for Specific Imaging of Intratumoral Complement System.

Advanced materials (Deerfield Beach, Fla.)·2026

Related Experiment Video

Updated: Nov 2, 2025

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.0K

Activatable molecular agents for cancer theranostics.

Jianjian Zhang1, Lulu Ning2, Jiaguo Huang3

  • 1Key Laboratory of Synthetic and Natural Functional Molecule Chemistry of Ministry of Education, Key Lab of Modern Separation Science in Shaanxi Province, College of Chemistry and Materials Science, Northwest University Xi'an 710127 Shaanxi P. R. China zhangjj@nwu.edu.cn.

Chemical Science
|June 14, 2021
PubMed
Summary

Activatable molecular agents (AMAs) offer advanced cancer theranostics by combining diagnosis and treatment. These agents enhance signal-to-noise ratio and therapeutic efficacy for personalized medicine.

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.4K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

935

Related Experiment Videos

Last Updated: Nov 2, 2025

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.0K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.4K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

935

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Oncology

Background:

  • Theranostics integrate diagnosis and treatment for personalized therapy and outcome monitoring.
  • Activatable molecular agents (AMAs) are crucial for effective theranostics.
  • AMAs offer improved signal-to-noise ratio, biomarker detection, and reduced toxicity.

Purpose of the Study:

  • To review recent advancements in activatable molecular agents for cancer theranostics.
  • To discuss the design principles, mechanisms, and applications of AMAs.
  • To explore the challenges and future directions of AMAs in cancer therapy.

Main Methods:

  • Literature review of recent research on AMAs in cancer theranostics.
  • Analysis of molecular design strategies for AMAs.
  • Evaluation of theranostic mechanisms including chemotherapy, photodynamic therapy, and photothermal therapy.

Main Results:

  • AMAs demonstrate significant potential in imaging-guided chemotherapy, photodynamic therapy, and photothermal therapy.
  • Key advancements in AMA design principles and theranostic mechanisms were highlighted.
  • Successful biomedical applications of AMAs in preclinical and clinical settings were discussed.

Conclusions:

  • AMAs represent a promising frontier in cancer theranostics, offering enhanced diagnostic and therapeutic capabilities.
  • Further research into AMA design and application is needed to overcome existing challenges.
  • AMAs hold potential for improving patient outcomes through personalized and real-time monitored cancer treatment.